SP-0113: Myth and reality of image guidance and adaptive treatments in proton therapy

M. Engelsman
2015 Radiotherapy and Oncology  
S54 3rd ESTRO Forum 2015 passing rate for target volumes was found to be above 96% for a 3%/3mm criteria. Differences in tumor control probability were within 2.5% for liver and breast, however, for head-and-neck and prostate patients the differences were up to 6.5% and up to 11% for lung patients. We conclude that approximations introduced in analytical dose calculation methods can result in significant range uncertainties for heterogeneous patient geometries or introduce a systematically
more » ... systematically reduced dose in target volumes. Routine MC simulations for treatment planning or verification may be necessary to ensure full target coverage to the prescribed dose levels. In particular for clinical trials comparing photon vs. proton treatments, MC simulations may be required to avoid bias due to differences in dose calculations.
doi:10.1016/s0167-8140(15)40111-2 fatcat:6d3etpasn5ecjaivlrkngwezl4